Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）.
Squamous Cell Non-small Cell Lung Cancer
DRUG: JMT101|DRUG: docetaxel|DRUG: HB1801
Overall response rate (ORR), Up to approximately 2 years|Overall Survival (OS), Up to approximately 3 years|Incidence and severity of adverse events (AE) and serious adverse events (SAE), Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0., Up to approximately 3 years
Progression-free Survival (PFS), PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first., Up to approximately 2 years|Disease Control Rate (DCR), Up to approximately 2 years|Duration of response（DOR）, Up to approximately 2 years|JMT101 Concentrations in Plasma, Up to approximately 2 years|Total and Free Docetaxel Concentrations in Plasma, Up to approximately 2 years
This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）.